

David Matthews

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/719631/publications.pdf>

Version: 2024-02-01

124
papers

72,884
citations

29994

54
h-index

19690

117
g-index

130
all docs

130
docs citations

130
times ranked

55985
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.	1.8	13
2	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 106-114.	2.2	19
3	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
4	An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. <i>International Journal of Cardiology</i> , 2021, 324, 165-172.	0.8	6
5	Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. <i>American Journal of Kidney Diseases</i> , 2021, 77, 23-34.e1.	2.1	38
6	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 822-831.	2.2	17
7	Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the <i>VERIFY</i> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 245-251.	2.2	13
8	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2021, 174, 141.	2.0	1
9	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	1.1	61
10	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	2.2	79
11	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2395-2401.	2.2	18
12	Exploring pain interference with motor skill learning in humans: a protocol for a systematic review. <i>BMJ Open</i> , 2021, 11, e045841.	0.8	2
13	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021, 64, 2012-2025.	2.9	24
14	Reasons for hospitalizations in patients with type 2 diabetes in the <i>CANVAS</i> programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.	2.2	6
15	Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 57-66.	1.9	93
16	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	2.2	54
17	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 530-539.	2.2	14
18	Insights from <i>VERIFY</i> : Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020, 11, 2465-2476.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	2.0	182
20	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the <sc>CANVAS</sc> Program. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2199-2203.	2.2	5
21	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. <i>Diabetologia</i> , 2020, 63, 1440-1452.	2.9	121
22	ADVANCE. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 3-4.	2.2	1
23	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	2.2	33
24	Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 3057-3063.	1.8	2
25	Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 1854-1867.	2.9	58
26	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2019, 394, 1519-1529.	6.3	210
27	Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lankans. <i>BMC Endocrine Disorders</i> , 2019, 19, 11.	0.9	15
28	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2240-2247.	2.2	8
29	Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2591-2593.	1.6	121
30	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 926-938.	2.9	94
31	The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. <i>Diabetes Therapy</i> , 2019, 10, 1-13.	1.2	15
32	Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2229-2242.	3.0	93
33	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 454-466.	2.2	129
34	Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes. <i>Diabetic Medicine</i> , 2019, 36, 505-513.	1.2	11
35	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. <i>Stroke</i> , 2019, 50, 396-404.	1.0	51
36	Prevalence, patterns, and associations of dyslipidemia among Sri Lankan adults—Sri Lanka Diabetes and Cardiovascular Study in 2005–2006. <i>Journal of Clinical Lipidology</i> , 2018, 12, 447-454.	0.6	23

#	ARTICLE	IF	CITATIONS
37	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. <i>Diabetes Care</i> , 2018, 41, 163-170.	4.3	46
38	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 889-897.	2.2	173
39	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. <i>Circulation</i> , 2018, 137, 323-334.	1.6	393
40	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	2.2	71
41	The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 1-14.	1.1	43
42	Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 691-704.	5.5	460
43	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Studyâ€“Renal (<scp>CANVASâ€“R</scp>): A randomized, placeboâ€“controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 387-393.	2.2	139
44	Optimizing the analysis strategy for the <scp>CANVAS</scp> Program: A prespecified plan for the integrated analyses of the <scp>CANVAS</scp> and <scp>CANVASâ€“R</scp> trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 926-935.	2.2	89
45	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 843-851.	0.9	19
46	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 644-657.	13.9	5,629
47	Junior hospital doctorsâ€“time to rethink the terminology. <i>Lancet, The</i> , 2017, 390, 2033-2034.	6.3	0
48	Prediction of 10â€“year vascular risk in patients with diabetes: the <scp>ADâ€“ON</scp> risk score. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 289-294.	2.2	21
49	Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. <i>Cardiovascular Diabetology</i> , 2016, 15, 129.	2.7	73
50	Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK). <i>BMC Endocrine Disorders</i> , 2016, 16, 42.	0.9	12
51	Community Interventions for Health can support clinicians in advising patients to reduce tobacco use, improve dietary intake and increase physical activity. <i>Journal of Clinical Nursing</i> , 2016, 25, 3167-3175.	1.4	2
52	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€“mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 82-91.	2.2	74
53	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , 2016, 39, 694-700.	4.3	184
54	Efficacy and safety of onceâ€“weekly glucagonâ€“like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	2.2	61

#	ARTICLE	IF	CITATIONS
55	Successful Up-Scaled Population Interventions to Reduce Risk Factors for Non-Communicable Disease in Adults: Results from the International Community Interventions for Health (CIH) Project in China, India and Mexico. PLoS ONE, 2015, 10, e0120941.	1.1	17
56	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58, 429-442.	2.9	598
57	Tobacco Smoking Among School Children in Colombo District, Sri Lanka. Asia-Pacific Journal of Public Health, 2015, 27, NP278-NP287.	0.4	6
58	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140â€“149. Diabetes Care, 2015, 38, e128-e129.	4.3	25
59	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Therapy, 2015, 6, 289-302.	1.2	36
60	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	4.3	2,326
61	Evaluation of Common Type 2 Diabetes Risk Variants in a South Asian Population of Sri Lankan Descent. PLoS ONE, 2014, 9, e98608.	1.1	8
62	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 2014, 371, 1392-1406.	13.9	520
63	Evaluation of physical activity among adults with diabetes mellitus from Sri Lanka. International Archive of Medicine, 2014, 7, 15.	1.2	16
64	Study to determine the durability of glycaemic control with early treatment with a vildagliptinâ€“metformin combination regimen vs. standardâ€“ofâ€“care metformin monotherapyâ€”the <sc>VERIFY</sc> trial: a randomized doubleâ€“blind trial. Diabetic Medicine, 2014, 31, 1178-1184.	1.2	35
65	Sodiumâ€“Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 262.	2.0	749
66	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)â€”A randomized placebo-controlled trial. American Heart Journal, 2013, 166, 217-223.e11.	1.2	290
67	Longâ€“term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2â€“year results from the <sc>LEAD</sc>â€“2 study. Diabetes, Obesity and Metabolism, 2013, 15, 204-212.	2.2	123
68	Expansion of the Homeostasis Model Assessment of Î²-Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2. Diabetes Care, 2013, 36, 2324-2330.	4.3	92
69	Methodology for Quantifying Fasting Glucose Homeostasis in Type 2 Diabetes: Observed Variability and Lability. Journal of Diabetes Science and Technology, 2013, 7, 640-645.	1.3	3
70	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum, 2012, 25, 154-171.	0.4	28
71	NIHR Diabetes Research Network: the gold standard for clinical trials?. Practical Diabetes, 2012, 29, 317-319.	0.1	0
72	NIHR Diabetes Research Network: recruitment, recruitment, recruitment. Practical Diabetes, 2012, 29, 369-370.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
74	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e1369-e1369.	2.4	356
75	ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. <i>Diabetologia</i> , 2012, 55, 2856-2857.	2.9	6
76	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2012, 55, 1577-1596.	2.9	1,718
77	Do clinical research networks work? The NIHR diabetes research network after 6 years. <i>Clinical Investigation</i> , 2012, 2, 971-974.	0.0	0
78	Community Interventions for Health (CIH): A novel approach to tackling the worldwide epidemic of chronic diseases. <i>CVD Prevention and Control</i> , 2011, 6, 47.	0.7	35
79	Banting Memorial Lecture 2010<sup>â€&sup>. Type 2 diabetes as an â€infectiousâ€ disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , 2011, 28, 2-9.	1.2	43
80	Banting Memorial Lecture: reply from Matthews and Matthews. Typeâ€2 diabetes as an â€infectiousâ€ disease: is this the Black Death of the 21st century?. <i>Diabetic Medicine</i> , 2011, 28, 880-880.	1.2	0
81	Remote assessment of diabetic foot ulcers using a novel wound imaging system. <i>Wound Repair and Regeneration</i> , 2011, 19, 25-30.	1.5	52
82	Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study. <i>Evidence-Based Medicine</i> , 2011, 16, 45-46.	0.6	9
83	Vildagliptin addâ€on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2â€year study. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 780-789.	2.2	178
84	Prevalence of overweight and obesity in Sri Lankan adults. <i>Obesity Reviews</i> , 2010, 11, 751-756.	3.1	99
85	Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. <i>Diabetes Care</i> , 2010, 33, 730-732.	4.3	76
86	Impending type 2 diabetes. <i>Lancet, The</i> , 2009, 373, 2178-2179.	6.3	4
87	An assessment of low carbohydrate or low fat diets for weight loss at two yearâ€s follow-up. <i>Diabetic Medicine</i> , 2009, 27, 363.	1.2	1
88	The diabetes epidemic in Sri Lanka â€ a growing problem. <i>Ceylon Medical Journal</i> , 2009, 51, 26.	0.1	35
89	N of 1 trials in diabetes: making individual therapeutic decisions. <i>Diabetologia</i> , 2008, 51, 921-925.	2.9	46
90	10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1577-1589.	13.9	6,543

#	ARTICLE	IF	CITATIONS
91	Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 359, 1565-1576.	13.9	674
92	Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 216-218.	0.9	40
93	Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. <i>Thorax</i> , 2007, 62, 969-974.	2.7	355
94	Grand challenges in chronic non-communicable diseases. <i>Nature</i> , 2007, 450, 494-496.	13.7	562
95	Higher body mass index is associated with irregular and suppressed insulin pulsatility. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 603-604.	2.2	2
96	The UK Diabetes Research Network-an opportunity and a challenge. <i>Diabetic Medicine</i> , 2007, 24, 7-9.	1.2	8
97	Pioglitazone/Metformin. <i>Drugs</i> , 2006, 66, 1878-1880.	4.9	0
98	Chris Feudtner, <i>Bittersweet: diabetes, insulin and the transformation of illness</i> , <i>Studies in Social Medicine</i> , Chapel Hill and London, University of North Carolina Press, 2003, pp. xxii, 290, illus., £22.95, US\$29.95 (hardback 0-8078-2791-6).. <i>Medical History</i> , 2005, 49, 117-118.	0.1	0
99	Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 167-174.	1.7	153
100	Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. <i>Diabetologia</i> , 2005, 48, 1093-1104.	2.9	160
101	Review: Sulphonylureas and the rise and fall of beta-cell function. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, 192-196.	0.6	3
102	Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 53-62.	1.1	77
103	Risks of Progression of Retinopathy and Vision Loss Related to Tight Blood Pressure Control in Type 2 Diabetes Mellitus. <i>JAMA Ophthalmology</i> , 2004, 122, 1631.	2.6	377
104	Recent advances in the monitoring and management of diabetic ketoacidosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2004, 97, 773-780.	0.2	88
105	An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. <i>Diabetic Medicine</i> , 2004, 21, 568-576.	1.2	108
106	Use and Abuse of HOMA Modeling. <i>Diabetes Care</i> , 2004, 27, 1487-1495.	4.3	4,019
107	Children with Type 2 Diabetes: The Risks of Complications. <i>Hormone Research in Paediatrics</i> , 2002, 57, 34-39.	0.8	35
108	Coefficient of failure: a methodology for examining longitudinal β -cell function in Type 2 diabetes. <i>Diabetic Medicine</i> , 2002, 19, 465-469.	1.2	44

#	ARTICLE	IF	CITATIONS
109	UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia, 2001, 44, 156-163.	2.9	840
110	Insulin resistance and β -cell function - a clinical perspective. Diabetes, Obesity and Metabolism, 2001, 3, 28-33.	2.2	36
111	The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice. Diabetic Medicine, 2001, 18, 640-645.	1.2	88
112	Dietary advice? Authors' response and erratum for "Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)". Diabetic Medicine, 2001, 18, 251-251.	1.2	0
113	Insulin resistance and beta-cell function - a clinical perspective. Diabetes, Obesity and Metabolism, 2001, 3 Suppl 1, 28-33.	2.2	3
114	Insulin resistance and beta-cell function--a clinical perspective. Diabetes, Obesity and Metabolism, 2001, 3 Suppl 1, S28-33.	2.2	6
115	Assessment of the effects of insulin secretagogues in humans. Diabetes, Obesity and Metabolism, 2000, 2, 271-283.	2.2	3
116	Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ: British Medical Journal, 2000, 321, 412-419.	2.4	1,737
117	Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ: British Medical Journal, 2000, 321, 405-412.	2.4	7,060
118	Microaneurysms in the development of diabetic retinopathy (UKPDS 42). Diabetologia, 1999, 42, 1107-1112.	2.9	124
119	UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. , 1998, 15, 297-303.		290
120	Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program. Diabetes Care, 1998, 21, 2191-2192.	4.3	1,745
121	Acute effect of fructose on postprandial lipaemia in diabetic and non-diabetic subjects. British Journal of Nutrition, 1998, 80, 169-175.	1.2	72
122	Unbiased and Flexible Iterative Computer Program to Achieve Glucose Clamping. Diabetes Care, 1989, 12, 156-159.	4.3	28
123	Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28, 412-419.	2.9	27,582
124	Control of pulsatile insulin secretion in man. Diabetologia, 1983, 24, 231-7.	2.9	157